Equities research analysts expect Teligent Inc (NASDAQ:TLGT) to announce sales of $15.62 million for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Teligent’s earnings. The highest sales estimate is $16.58 million and the lowest is $15.10 million. Teligent reported sales of $19.89 million during the same quarter last year, which would suggest a negative year over year growth rate of 21.5%. The business is scheduled to announce its next quarterly earnings report on Tuesday, May 1st.
According to Zacks, analysts expect that Teligent will report full year sales of $15.62 million for the current financial year, with estimates ranging from $74.05 million to $76.80 million. For the next fiscal year, analysts forecast that the company will report sales of $104.16 million per share, with estimates ranging from $96.55 million to $110.80 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Teligent.
Teligent (NASDAQ:TLGT) last released its quarterly earnings results on Thursday, March 15th. The company reported ($0.08) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.13) by $0.05. The firm had revenue of $16.10 million for the quarter, compared to analysts’ expectations of $13.54 million. Teligent had a negative net margin of 18.42% and a negative return on equity of 14.55%.
Teligent stock opened at $3.36 on Friday. The company has a current ratio of 2.68, a quick ratio of 2.01 and a debt-to-equity ratio of 2.70. Teligent has a twelve month low of $2.43 and a twelve month high of $9.54.
Several large investors have recently made changes to their positions in TLGT. AMI Asset Management Corp grew its position in shares of Teligent by 46.4% during the 4th quarter. AMI Asset Management Corp now owns 2,339,968 shares of the company’s stock worth $8,494,000 after purchasing an additional 741,818 shares in the last quarter. Broadfin Capital LLC grew its position in shares of Teligent by 35.1% during the 4th quarter. Broadfin Capital LLC now owns 1,925,415 shares of the company’s stock worth $6,989,000 after purchasing an additional 500,000 shares in the last quarter. Stifel Financial Corp grew its position in shares of Teligent by 51.7% during the 3rd quarter. Stifel Financial Corp now owns 1,141,741 shares of the company’s stock worth $7,685,000 after purchasing an additional 389,307 shares in the last quarter. Citadel Advisors LLC acquired a new position in shares of Teligent during the 3rd quarter worth approximately $1,297,000. Finally, Kopp Investment Advisors LLC boosted its position in shares of Teligent by 24.2% during the 4th quarter. Kopp Investment Advisors LLC now owns 956,526 shares of the company’s stock worth $3,472,000 after acquiring an additional 186,390 shares in the last quarter. Hedge funds and other institutional investors own 68.24% of the company’s stock.
Teligent, Inc is a specialty generic pharmaceutical company. Under the Company’s own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 16 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2016.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Teligent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent and related companies with MarketBeat.com's FREE daily email newsletter.